Squamous Cell Neoplasm

IHC for expression of ALDH1A2 and CRABP2 was performed in 89 patients with squamous cell carcinoma of the head and neck. High expression of both, ALDH1A2 and CRABP2 (in comparison to ALDH1A2 low or AL… (full text at CIViC)

PMID 26634247 · Seidensaal et al., 2015 · Open in CIViC

ALDH1A2 protein levels were determined (IHC) in 115 patients with oropharyngeal squamous cell carcinoma with known HPV status (n = 89 non–HPV-driven; n = 26 HPV-driven). Low to moderate ALDH1A2 protei… (full text at CIViC)

PMID 23635773 · Kostareli et al., 2013 · Open in CIViC

FaDu (a high ALDH1A2 expression cell line) and Cal27 (a low expression cell line) were treated with all-trans retinoic acid (ATRA), Adapalene or Fenretinide. This led to concentration dependent decrea… (full text at CIViC)

PMID 26634247 · Seidensaal et al., 2015 · Open in CIViC

47 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR and AREG expression with IHC. 45% of cases expressed high level of AREG. High AREG expression in tum… (full text at CIViC)

PMID 21653686 · Tinhofer et al., 2011 · Open in CIViC

47 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR and AREG expression with IHC. 45% of cases expressed high level of AREG. High AREG expression in tum… (full text at CIViC)

PMID 21653686 · Tinhofer et al., 2011 · Open in CIViC

A retrospective study examining the expression of AURKA in tumor samples of 78 esophageal squamous cell carcinoma patients found that positive expression of AURKA (>10% of cells by IHC) was correlated… (full text at CIViC)

PMID 25924824 · Tamotsu et al., 2015 · Open in CIViC

Concurrent inhibition of both AURKB (and AURKA) and PI3K is synergistic in NOTCH1-wild type and NOTCH-1 mutant head and neck squamous cell carcinoma (HNSCC) cell lines. In NOTCH1-wt cell lines, the co… (full text at CIViC)

PMID 36169922 · Shah et al., 2022 · Open in CIViC

Immunohistochemical analysis of tumors from 116 esophageal squamous cell carcinoma found that expression of AXL was associated with increased progression of the tumor (P < 0.0001), increased risk of d… (full text at CIViC)

PMID 27172793 · Hsieh et al., 2016 · Open in CIViC

The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One patient … (full text at CIViC)

PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC

In a phase II trial, patients with squamous non-small cell lung cancer who had progressed at least one prior platinum-based chemotherapy with CCND1/2/3 or CDK 4 amplification were treated with palboci… (full text at CIViC)

PMID 31302234 · Edelman et al., 2019 · Open in CIViC

Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis in head and neck squamous cell carcinoma.

PMID 16309541 · Thomas et al., 2005 · Open in CIViC

In a phase II trial, patients with squamous non-small cell lung cancer who had progressed at least one prior platinum-based chemotherapy with CCND1/2/3 or CDK 4 amplification were treated with palboci… (full text at CIViC)

PMID 31302234 · Edelman et al., 2019 · Open in CIViC

In a phase II trial, patients with squamous non-small cell lung cancer who had progressed at least one prior platinum-based chemotherapy with CCND1/2/3 or CDK 4 amplification were treated with palboci… (full text at CIViC)

PMID 31302234 · Edelman et al., 2019 · Open in CIViC

In this study, PD-L1 expression (measured by IHC) was associated with better overall survival in the subgroup of Lung Squamous Cell Carcinomas (149 of 321 patients in the study).

PMID 26313362 · Schmidt et al., 2015 · Open in CIViC

Radiation-resistant cell lines exhibited upregulation and increased activation of Axl, PI3 kinase signalling as well as increased expression of PD-L1. In 3 cohorts of HPV-negative head and neck squamo… (full text at CIViC)

PMID 28476872 · Skinner et al., 2017 · Open in CIViC

In a clinical study including 82 patients, a Kaplan-Meier analysis showed a significant association between CD44v6 expression (high and low) and worse disease-free survival (p = 0.03). Another Kaplan-… (full text at CIViC)

PMID 19507218 · Wang et al., 2009 · Open in CIViC

In 72 nonchemioradioselected (N-CRS) patients the CD44v9-positive by immunohistochemistry staining group demonstrated worse disease-specific survival than the CD44v9-negative groupe (p = 0.008) after … (full text at CIViC)

PMID 25751671 · Aso et al., 2015 · Open in CIViC

41 HNSSC were analyzed by IHC for expression of EGFR, p53, CCND1, p16, p21, p27 (CDKN2B), p-AKT, HIF-1a, Caspase 3 and BCL2. p27 was the only protein that served as a predictive biomarker of response … (full text at CIViC)

PMID 24239278 · Moreno-Galindo et al., 2014 · Open in CIViC

p16 positivity, as a surrogate marker for HPV-associated HNSSC was a favorable prognostic marker in recurrent or metastatic carcinoma.

PMID 24799460 · Argiris et al., 2014 · Open in CIViC

Patients from three studies (RTOG 0129, 0234, and 0522; 85, 95 and 142 patients, respectively) were retrospectively analyzed for p16 (CDKN2A) expression (IHC) and HPV-high risk status (ISH). p16 expre… (full text at CIViC)

PMID 25267748 · Chung et al., 2014 · Open in CIViC

124 esophageal squamous cell carcinoma patients with radical resection were genotyped using MassArray. The TC/CC genotype of p14ARF at rs3814960 had decreased overall survival (HR = 2.77, 95% CI: 1.3… (full text at CIViC)

PMID 27414035 · Li et al., 2016 · Open in CIViC

Assessment of beta-catenin mutations in a large collections of pituitary adenomas (n=60) and craniopharynangiomas (n=41), identified CTNNB1 exon 3 mutations in 77% of craniopharynangiomas, all of the … (full text at CIViC)

PMID 15891929 · Buslei et al., 2005 · Open in CIViC

Whole-exome sequencing identified CTNNB1 mutations in 11 of 12 (92%) of adamantinomatous craniopharyngiomas examined. No other recurrent mutations or genomic aberrations were identified. Targeted se… (full text at CIViC)

PMID 24413733 · Brastianos et al., 2014 · Open in CIViC

The NCI-H2286 lung squamous cell carcinoma cell line, containing the DDR2 I638F mutation was shown to be sensitive (IC50 139nm) to dasatinib in-vitro. Dasatanib sensitivity was demonstrated in-vivo us… (full text at CIViC)

PMID 22328973 · Hammerman et al., 2011 · Open in CIViC

In a patient expressing a DDR2 S768R mutation, treatment with dasatinib plus erlotinib acheived a partial response.

PMID 22328973 · Hammerman et al., 2011 · Open in CIViC

The primary tumor of A patient with head and neck squamous cell carcinoma with lung metastasis was not surgically resectable. Initial treatments led to stable disease and progression after 1 year. The… (full text at CIViC)

PMID 31011208 · Yang et al., 2019 · Open in CIViC

A 69 year old patient diagnosed with HNSCC presented with an unresectable neck mass three months after surgery and adjuvant radiation therapy. A biopsy was taken for whole genome and transcriptome ana… (full text at CIViC)

PMID 31871216 · Majounie et al., 2020 · Open in CIViC

3 tongue cancer cell lines were used for this study. Addition of recombinant human EGF led to increased cetuximab resistance. EGF downregulation suppressed proliferation of cell lines. Results for amp… (full text at CIViC)

PMID 25677871 · Ansell et al., 2016 · Open in CIViC

The group of 43 out of 75 tumor samples with increased copy number or amplification of EGFR as determined by FISH (FISH-positive) had worse progression-free and overall survival than FISH-negative tum… (full text at CIViC)

PMID 16943533 · Chung et al., 2006 · Open in CIViC

In patients with cervical squamous cell carcinoma, those with gene amplification of EGFR had worse overall survival.

PMID 21730982 · Iida et al., 2011 · Open in CIViC

In 134 patients with head and neck squamous cancer 32 had copy number variations. Tumors with variation (either increase or decrease) in copy number of EGFR had worse overall, cancer-specific, and dis… (full text at CIViC)

PMID 17538160 · Temam et al., 2007 · Open in CIViC

A patient with stage IV lung squamous cell carcinoma harboring an EGFR G719C mutation and high PD-L1 expression (tumor proportion score of 90%) experienced disease progression after 1.5 months of afat… (full text at CIViC)

PMID 40959071 · Fu et al., 2025 · Open in CIViC

This retrospective preclinical study assessed the efficacy of afatinib towards esophageal squamous cell carcinoma (ESCC) cell lines expressing EGFR L861Q mutation. In one experiment, a ESCC KYSE270 EG… (full text at CIViC)

PMID 27207775 · Nakamura et al., 2016 · Open in CIViC

Primary tumors of 91 patients with head and neck squamous cell carcinoma were analyzed for expression of EGFR and TGF-alpha using IHC. Expression of EGFR or TGF-alpha were associated with reduced dise… (full text at CIViC)

PMID 9625170 · Rubin Grandis et al., 1998 · Open in CIViC

55 tumor samples were analyzed for EGFR expression using IHC. PFS and OS was shorter for the EGFR high expressing group (18 pts) than for the low to moderate expression group (37 pts). PFS: 5.8 ± 0.5 … (full text at CIViC)

PMID 26459251 · Jia et al., 2016 · Open in CIViC

bp] In an in vitro study, a NIH3T3 cell line expressing EGFR P546S mutation demonstrated increased sensitivity to cetuximab treatment compared to NIH-3T3 cells expressing EGFR wild-type. Sensitivity w… (full text at CIViC)

PMID 23578570 · Bahassi et al., 2013 · Open in CIViC

72-year old male patient presents with SCC with a mutation profile consistent with UV exposure. Sequencing revealed a number of abnormalities including P753S mutation in EGFR. Patient began therapy wi… (full text at CIViC)

PMID 24934779 · Ganesan et al., 2016 · Open in CIViC